DCGI approves AstraZeneca Olaparib tablets for ovarian and breast cancer

▴ astrazeneca-olaparib-tablets-treating-ovarian-and-breast-cancer-approved
AstraZeneca's patented olaparib for ovary and breast cancer now in India

Drug firm AstraZeneca Pharma India today said it has received permission from the Drug Controller General of India (DCGI) to import and market olaparib tablets used for the treatment of ovarian and breast cancer.

The permission from the DCGI is for olaparib (Lynparza) tablets in the strengths of 100 mg and 150 mg, AstraZeneca Pharma India said in a BSE filing.The tablets are a patented product of the AstraZeneca group, it added.

"The import and market permission for olaparib is a significant milestone for women in India living with platinum-sensitive relapsed ovarian cancer and BRCA-mutated HER-2 negative metastatic breast cancer, which has historically been difficulty-to-treat diseases," AstraZeneca Pharma India MD Gagan Singh said.

Shares of AstraZeneca Pharma India yeerdayat Rs 1,710.30 per scrip on BSE, up 1.59 per cent from their previous close.

AstraZeneca India was established in 1979 and is headquartered at Bengaluru, Karnataka. AstraZeneca Pharma India Limited (AZPIL) is the operating company and covers manufacturing, sales and marketing activities of the company in India. It is a listed company and is a subsidiary of AstraZeneca Plc, UK. It has a workforce of over 1400 employees across the country that is committed to deliver life-changing medicines to patients through innovative science and global excellence in development and commercialization. The company has an innovative portfolio in crucial areas of healthcare including cardiovascular, renal & metabolic diseases, oncology and respiratory.


Rated as one of the finest in South East Asia, AstraZeneca’s Indian manufacturing facility has a sophisticated production facility designed to meet the most stringent international standards, conforming to WHO cGMP (current Good Manufacturing Practices) norms. The facility is an ISO 14001 certified company and has a full-fledged environment management system in place.

AstraZeneca India Private Limited (AZIPL) hosts the IT (Global Technology Centre), Global Business Services (Global Commercial Operations) and GMD (Global Medicines Development). AZIPL is governed by a Board of Directors.

Inputs- PTI

Tags : #AstraZeneca #DCGI #OvarianCancer #BreastCancer #AZPL #Karnataka #LatestPharmaNewsAug20 #LatestPharmaUpdateAug20

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Scientists in Moscow Develop Fetal Phantom for Obstetric UltrasoundNovember 19, 2024
International Men’s Day: A Celebration of Strength, Vulnerability, and ChangeNovember 19, 2024
The Bloody Truth: Why Menstruation Is Still a Taboo in Indian SchoolsNovember 19, 2024
Toxic Air, Fragile Hearts: The Hidden Cost of Pollution on Heart Failure PatientsNovember 19, 2024
Government of Telangana Hosts the AI in Healthcare Summit – Road to BioAsia 2025November 18, 2024
In yet another groundbreaking medical milestone, Sarvodaya Hospital successfully performs India’s youngest cochlear implant on a 5- month old babyNovember 18, 2024
Sightsavers India in collaboration with AbbVie Therapeutics India Private Limited Hosted the 4th State-Level Consultation on ‘Prevention of Visual Impairment Caused by Glaucoma’November 16, 2024
Is Your Saree Hurting You? How Tight Waist Petticoats Could Trigger Skin CancerNovember 16, 2024
10 New-born Lives Lost: The Jhansi Hospital Fire That Shook India’s ConscienceNovember 16, 2024
Streax introduces revolutionary Shampoo Hair Colour in South India at accessible price point.November 15, 2024
The Silent Killer in Your Genes: Can Splicing Errors Unlock New Cancer Cures?November 15, 2024
Stress on a Schedule: What Your Gut Bacteria Know That You Don’tNovember 15, 2024
A Preventable Catastrophe: Why Are Children Still Dying from Measles?November 15, 2024
The University of Tasmania invites applications for Master of Marine and Antarctic ScienceNovember 14, 2024
ICMR’s Bold Bet: Can India’s Scientists Deliver World-First Health Breakthroughs?November 14, 2024
The Dark Reality Behind India’s Ayushman Bharat: Profits Before Patients?November 14, 2024
Not a Fan of Exercise? Here’s How Few Steps You Actually Need for Better HealthNovember 14, 2024
Shiprocket launches AI Powered Shiprocket Copilot to empower a Self-Reliant Digital Future for over 1,00,000+ Indian MSMEsNovember 13, 2024
AIIMS Darbhanga and More: Can PM Modi’s 12,000 Crore Investment Turn Bihar into India’s Next Growth Engine?November 13, 2024
Self-Made Survivor: How a Virologist Battled Breast Cancer with Her Own Lab-Grown VirusesNovember 13, 2024